What is RedShiftBio?
RedShiftBio has developed a proprietary analytical technique known as Microfluidic Modulation Spectroscopy (MMS). This patented technology offers a comprehensive approach to probing the biophysical structure of proteins, providing detailed secondary structure information across five key measurements within a single, automated analysis. This capability aims to streamline and enhance the research, development, and manufacturing processes for protein therapeutic drugs, potentially replacing the need for multiple, disparate analytical instruments.
How much funding has RedShiftBio raised?
RedShiftBio has raised a total of $71.7M across 9 funding rounds:
Series B
$6.2M
Private Equity
$2.4M
Private Equity
$751K
Private Equity
$1M
Series C
$11M
Series D
$18M
Debt
$350K
Series E
$20M
Series B (2008): $6.2M led by Technology Venture Partners, Emerson Ventures, InterWest Partners, and Alta California Partners
Private Equity (2012): $2.4M, investors not publicly disclosed
Private Equity (2014): $751K featuring Technology Venture Partners, LLC
Private Equity (2015): $998K, investors not publicly disclosed
Series C (2017): $11M with participation from Waters and Technology Venture Partners
Series D (2020): $18M, investors not publicly disclosed
Debt (2020): $350K supported by PPP
Series E (2021): $20M featuring Illumina Ventures, Waters, and Technology Venture Partners
Key Investors in RedShiftBio
Waters
Waters is a key player in scientific solutions, providing instruments and software that ensure the safety and quality of medicines, food, and everyday products. Their investment in RedShiftBio suggests a strategic interest in advancing biopharmaceutical analysis and drug development.
Technology Venture Partners
Technology Venture Partners is a venture capital firm focused on high-potential technology companies. Their involvement indicates a belief in RedShiftBio's innovative technology and market potential within the analytical instrumentation space.
Illumina Ventures
Illumina Ventures is a venture capital firm specializing in genomics and precision health, aiming to translate investment into innovation for human health. Their participation highlights RedShiftBio's alignment with advancements in life sciences and biopharmaceutical drug development.
What's next for RedShiftBio?
The substantial enterprise-level funding and recent strategic investment indicate RedShiftBio is poised for significant scaling and market expansion. This capital infusion is likely to accelerate product development, enhance manufacturing capabilities, and broaden the company's commercial reach. The company's focus on advanced protein analysis positions it to capitalize on the growing biopharmaceutical sector, particularly in areas requiring precise characterization of complex protein therapeutics.
See full RedShiftBio company page
